Down syndrome and beta-amyloid deposition

Current Opinion in Neurology

Volumn 17, Issue 2, 2004, Pages 95-100

  Head, Elizabeth ^a,b   Lott, Ira T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BACE; Insulin degrading enzyme; Neprilysin; Oligomers; Tissue plasminogen activators

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE;

AGING; ALZHEIMER DISEASE; BIOACCUMULATION; CHROMOSOME 21; DOWN SYNDROME; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SENILE PLAQUE;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; AMYLOIDOSIS, FAMILIAL; ASPARTIC ENDOPEPTIDASES; BRAIN; CHILD; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIPID PEROXIDATION; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 1842610580     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200404000-00003     Document Type: Review

References (62)

1. Mann DMA. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 1988; 43:99-136.
2. Mann DMA, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 1989; 89:169-179.
3. Wisniewski K, Wisniewski H, Wen G. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurology 1985; 17:278-282.
4. Hof PR, Bouras C, Perl DP, et al. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Arch Neurol 1995; 52:379-391.
5. Lai F, Williams MD. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989; 46:849-853.
6. Irizarry MC, Hyman BT. Alzheimer disease therapeutics. J Neuropathol Exp Neurol 2001; 60:923-928.
7. Rumble B, Retallack R, Hilbich C, et al. Amyloid A4 and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 1989; 320:1446-1462.
8. Nunan J, Small DH. Regulation of APP cleavage by α-, β- and γ-secretases. FEBS Lett 2000; 483:6-10.
9. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994; 17:489-517.
10. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286:735-741.
11. Barbiero L, Benussi L, Ghidoni R, et al. BACE-2 is overexpressed in Down's syndrome. Exp Neurol 2003; 182:335-345. The authors characterized both the gene and protein expression of BACE-2, and an enzyme important for the cleavage of Aβ from APP, which is present on chromosome 21. An increase in secreted BACE-2 was observed in DS fibroblasts and overexpression was also confirmed in fetal brain tissue.
12. Motonaga K, Itoh M, Becker LE, et al. Elevated expression of betasite amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome. Neurosci Lett 2002; 326:64-66.
13. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996; 2:93-95.
14. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 2001; 301:199-203.
15. Cavani S, Tamaoka A, Moretti A, et al. Plasma levels of amyloid β 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet 2000; 95:224-228.
16. Mehta PD, Dalton AJ, Mehta SP, et al. Increased plasma amyloid β protein 1-42 levels in Down syndrome. Neurosci Lett 1998; 241:13-16.
17. Tapiola T, Soininen H, Pirttila T. CSF tau and Aβ42 levels in patients with Down's syndrome. Neurology 2001; 56:979-980.
18. Walsh DM, Klyubin I, Fadeeva JV, et al. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002; 30:552-557.
19. Lambert MP, Barlow AK, Chromy BA, et al. Diffusable, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95:6448-6453.
20. Cummings BJ. Plaques and tangles: searching for primary events in a forest of data. Neurobiol Aging 1997; 18:358-362.
21. Van Dam D, D'Hooge R, Staufenbiel M, et al. Age-dependent cognitive decline in APP23 model precedes amyloid deposition. Eur J Neurosci 2003; 17:388-396.
22. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002; 22:1858-1867.
23. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996; 271:4077-4081.
24. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300:486-489.
25. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Prac Natl Acad Sci U S A 2003; 100:10417-10422.
26. Gyure KA, Durham R, Stewart WF, et al. Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 2001; 125:489-492.
27. Mon C, Spooner ET, Wisniewski KE, et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 2002; 9:88-102. The authors examined the location of several species of Aβ and observed significant intracellular Aβ1-42 immunohistochemistry in the temporal cortex from 70 individuals ranging in age from 3 to 73 years. In addition, more extensive intracellular Aβ1-42 was observed in young individuals (3-4 years) but decreased as extracellular Aβ1-42 increased. The authors also provide evidence that intracellular Aβ could be clearly distinguished from intracellular APP.
28. Gouras GK, Tsai J, Naslund J, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000; 156:15-20.
29. Head E, Lott IT, Cribbs DH, et al. Beta-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome. Neurosci Lett 2002; 330:99-103.
30. Hirayama A, Horikoshi Y, Maeda M, et al. Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome. Brain Dev 2003; 25:180-185.
31. Knauer MF, Soreghan B, Burdick D, et al. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci U S A 1992; 89:7437-7441.
32. Yang AJ, Chandswangbhuvana D, Shu T, et al. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J Biol Chem 1999; 274:20650-20656.
33. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's Disease. J Mol Neurosci 2001; 17:137-145.
34. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003; 39:409-421.
35. Wirth O, Multhaup G, Czech C, et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 2001; 306:116-120.
36. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002; 81:1-8.
37. Melchor JP, Pawlak R, Stickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-β (Aβ) degradation and inhibits Aβ-induced neurodegeneration. J Neurosci 2003; 23:8867-8871.
38. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001; 32:177-180.
39. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 1993; 90:7915-7922.
40. Brooksbank BW, Balazs R. Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res 1984; 318:37-44.
41. Iannello RC, Crack PJ, de Haan JB, Kola I. Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm 1999; 57:257-267.
42. Nunomura A, Perry G, Pappolla M, et al. Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome. J Neuropathol Exp Neurol 2000; 59:1011-1017.
43. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995; 378:776-779.
44. Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Rad Biol Med 1998; 25:1044-1048.
45. Pratico D, Iuliano L, Amerio G, et al. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol 2000; 48:795-798.
46. Pratico D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001; 21:4183-4187.
47. Huang X, Atwood CS, Hartshorn MA, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38:7609-7616.
48. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 2000; 130:184-208.
49. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77:817-827.
50. Busciglio J, Pelsman A, Wong C, et al. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 2002; 33:677-688. The authors show that neuronal cultures derived from fetal DS brain accumulate intracellular Aβ and abnormal APP processing. These abnormalities can be paralleled in astrocyte cultures by the inhibition of mitochondrial metabolism. Early abnormal APP processing may thus be caused by mitochondrial dysfunction in DS.
51. Wang D-S, Iwata N, Hama E, et al. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem Biophys Res Commun 2003; 310:236-241.
52. Lim GP, Chu T, Beech W, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21:8370-8377.
53. Begni B, Brighina L, Fumagalli L, et al. Altered glutamate uptake in peripheral tissues from Down syndrome patients. Neurosci Lett 2003; 343:73-76. The authors detected a significant decrease in peripheral glutamate uptake in platelets and fibroblasts from individuals with DS compared with age-matched controls, indicating possible glutaminergic system dysfunction.
54. Simpson MDC, Slater P, Cross AJ, et al. Reduced d-[3H] aspartate binding in Down's syndrome brains. Brain Res 1989; 484:273-278.
55. 7 nicotinic acetylcholine receptor: therapeutic implications. Clin Neuropharmacol 2003; 26:277-283. The authors provide a review of the interaction between soluble Aβ and nicotinic acetylcholine receptors along with therapeutic implications for individuals with DS.
56. Lott IT, Osann K, Doran E, Nelson L. Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol 2002; 59:1133-1136.
57. Pakasi M, Kasa P. Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr Drug Target CNS Neurol Disord 2003; 2:163-171.
58. Schupf N. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 2002; 180:405-410. The author provides an excellent review of risk factors for the development of dementia in adults with DS, and describes the possible role of apolipoprotein E, estrogen deficiency and individual high levels of Aβ1-42.
59. Head E, Azizeh BY, Lott IT, et al. Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down syndrome. Neurobiol Dis 2001; 8:252-265.
60. Griffin WS, Stanley LC, Ling C, et al. Brain interteukin I and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc Natl Acad Sci U S A 1989; 86:7611-7615.
61. Head E, Lott IT, Hof PR, et al. Parallel compensatory and pathological events associated with tau pathology in middle aged individuals with Down syndrome. J Neuropathol Exp Neurol 2003; 62:917-926. The authors provide evidence of compensatory growth response by neurons in the DS hippocampus at ages immediately before the development of full-blown AD pathology.
62. Haier R, Alkire MT, White NS, et al. Temporal cortex hypermetabolism in Down syndrome suggests neuronal compensation before dementia. Neurology 2003; 61:1673-679. The authors provide in vivo PET imaging results suggesting temporal cortex hypermetabolism may occur in adults with Down syndrome prior to the onset of dementia signaling a possible compensatory response.